J Prinz1, Y d'Hargues1, P Gödel1, A Shimabukuro-Vornhagen1, M Kochanek1, B Böll2. 1. Klinik I für Innere Medizin, Uniklinik Köln, Kerpener Str. 62, 50937, Köln, Deutschland. 2. Klinik I für Innere Medizin, Uniklinik Köln, Kerpener Str. 62, 50937, Köln, Deutschland. boris.boell@uk-koeln.de.
Abstract
BACKGROUND: The development of chimeric antigen receptor (CAR) T‑cells has shown promising results in relapsed/refractory B‑cell acute lymphoblastic leukemia/lymphoma (B-ALL) and diffuse large cell B‑cell lymphoma. Complications, especially cytokine release syndrome (CRS) and CAR T‑cell related encephalopathy syndrome (CRES), can be life threatening. The management of both plays a key role in CAR T‑cell therapy. OBJECTIVES: Diagnosis, clinical presentation and development of complications in the treatment with CAR T‑cells. MATERIALS AND METHODS: Summary of incidence, mortality and treatment of severe complications after administration of CAR T‑cells referring to current studies and therapy recommendations. RESULTS: Complications after administration of CAR T‑cells, especially CRS and CRES, can be life threatening. The timely identification of side effects and their appropriate treatment usually leads to complete recovery. CONCLUSIONS: Using a therapy algorithm in the treatment with CAR T‑cells allows safe management of toxicities and can be helpful in recognizing them in time.
BACKGROUND: The development of chimeric antigen receptor (CAR) T‑cells has shown promising results in relapsed/refractory B‑cell acute lymphoblastic leukemia/lymphoma (B-ALL) and diffuse large cell B‑cell lymphoma. Complications, especially cytokine release syndrome (CRS) and CAR T‑cell related encephalopathy syndrome (CRES), can be life threatening. The management of both plays a key role in CAR T‑cell therapy. OBJECTIVES: Diagnosis, clinical presentation and development of complications in the treatment with CAR T‑cells. MATERIALS AND METHODS: Summary of incidence, mortality and treatment of severe complications after administration of CAR T‑cells referring to current studies and therapy recommendations. RESULTS: Complications after administration of CAR T‑cells, especially CRS and CRES, can be life threatening. The timely identification of side effects and their appropriate treatment usually leads to complete recovery. CONCLUSIONS: Using a therapy algorithm in the treatment with CAR T‑cells allows safe management of toxicities and can be helpful in recognizing them in time.
Entities:
Keywords:
CAR T‑cell-related encephalopathy syndrome; CAR T‑cells; Cytokine release syndrome; Interleukin-6; Tocilizumab
Authors: James N Kochenderfer; Robert P T Somerville; Tangying Lu; James C Yang; Richard M Sherry; Steven A Feldman; Lori McIntyre; Adrian Bot; John Rossi; Norris Lam; Steven A Rosenberg Journal: Mol Ther Date: 2017-07-13 Impact factor: 11.454
Authors: Kevin A Hay; Laïla-Aïcha Hanafi; Daniel Li; Juliane Gust; W Conrad Liles; Mark M Wurfel; José A López; Junmei Chen; Dominic Chung; Susanna Harju-Baker; Sindhu Cherian; Xueyan Chen; Stanley R Riddell; David G Maloney; Cameron J Turtle Journal: Blood Date: 2017-09-18 Impact factor: 22.113
Authors: G Plenz; Z F Song; T D Tjan; C Koenig; H A Baba; M Erren; M Flesch; T Wichter; H H Scheld; M C Deng Journal: Eur J Heart Fail Date: 2001-08 Impact factor: 15.534
Authors: Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens Journal: Sci Transl Med Date: 2014-02-19 Impact factor: 17.956